169 related articles for article (PubMed ID: 8688335)
1. Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant.
Kuramitsu Y; Nishibe M; Kobayashi M; Togashi Y; Yuan L; Takizawa M; Okada F; Hosokawa M
Br J Cancer; 1996 Jul; 74(2):274-9. PubMed ID: 8688335
[TBL] [Abstract][Full Text] [Related]
2. [Mechanisms of enhanced accumulation of transferred LAK cells into tumor sites after chemotherapy].
Kuramitsu Y
Hokkaido Igaku Zasshi; 1995 May; 70(3):507-17. PubMed ID: 7590601
[TBL] [Abstract][Full Text] [Related]
3. Augmented accumulation of transferred lymphokine-activated killer (LAK) cells at murine tumor sites through production of LAK-attractant facilitated by chemotherapy.
Hosokawa M; Wakizaka Y; Kuramitsu Y; Micallef M; Togashi Y; Kobayashi H
Tohoku J Exp Med; 1992 Oct; 168(2):413-6. PubMed ID: 1306328
[TBL] [Abstract][Full Text] [Related]
4. Tumor-derived transforming growth factor-beta 1 and interleukin-6 are chemotactic for lymphokine-activated killer cells.
Delens N; Torreele E; Savelkool H; De Baetselier P; Bouwens L
Int J Cancer; 1994 Jun; 57(5):696-700. PubMed ID: 8194878
[TBL] [Abstract][Full Text] [Related]
5. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
6. Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.
Brooks B; Chapman K; Lawry J; Meager A; Rees RC
Clin Exp Immunol; 1990 Dec; 82(3):583-9. PubMed ID: 2124961
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta inhibits lymphokine activated killer cytotoxicity of bone marrow cells: implications for the graft-versus-leukemia effect in irradiation allogeneic bone marrow chimeras.
Billiau AD; Sefrioui H; Overbergh L; Rutgeerts O; Goebels J; Mathieu C; Waer M
Transplantation; 2001 Jan; 71(2):292-9. PubMed ID: 11213076
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.
Gazit Z; Kedar E
Cancer Immunol Immunother; 1994 Apr; 38(4):243-52. PubMed ID: 8168119
[TBL] [Abstract][Full Text] [Related]
9. Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.
Yoneda K; Osaki T; Yamamoto T; Ueta E
Clin Exp Immunol; 1993 Aug; 93(2):229-36. PubMed ID: 8348749
[TBL] [Abstract][Full Text] [Related]
10. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
Puri RK; Leland P
Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta 1 is chemotactic for interleukin-2-activated natural killer cells.
Maghazachi AA; al-Aoukaty A
Nat Immun; 1993; 12(2):57-65. PubMed ID: 8318816
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of in vitro prostaglandin E2 production by mouse fibrosarcoma cells after co-culture with various anti-tumour effector cells.
Okada F; Hosokawa M; Hasegawa J; Kuramitsu Y; Nakai K; Yuan L; Lao H; Kobayashi H; Takeichi N
Br J Cancer; 1994 Aug; 70(2):233-8. PubMed ID: 8054271
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors.
Maghazachi AA
Immunology; 1990 Aug; 70(4):465-72. PubMed ID: 2118478
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta 1 down-regulates expression of membrane-associated lymphotoxin and secretion of soluble lymphotoxin by human lymphokine-activated killer T cells in vitro.
Abe Y; Miyake M; Osuka Y; Kimura S; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1992 Oct; 11(5):245-51. PubMed ID: 1467364
[TBL] [Abstract][Full Text] [Related]
15. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.
Smyth MJ; Strobl SL; Young HA; Ortaldo JR; Ochoa AC
J Immunol; 1991 May; 146(10):3289-97. PubMed ID: 1827481
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor necrosis factor-alpha and -beta secretion by lymphokine activated killer cells by transforming growth factor-beta.
Naganuma H; Sasaki A; Satoh E; Nagasaka M; Nakano S; Isoe S; Tasaka K; Nukui H
Jpn J Cancer Res; 1994 Sep; 85(9):952-7. PubMed ID: 7961125
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity.
Hsiao YW; Liao KW; Hung SW; Chu RM
J Immunol; 2004 Feb; 172(3):1508-14. PubMed ID: 14734728
[TBL] [Abstract][Full Text] [Related]
18. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
Espevik T; Figari IS; Ranges GE; Palladino MA
J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
[TBL] [Abstract][Full Text] [Related]
20. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
